Genetic susceptibility of COVID-19: a systematic review of current evidence

SeyedAlinaghi, SeyedAhmad; Mehrtak, Mohammad; MohsseniPour, Mehrzad; Mirzapour, Pegah; Barzegary, Alireza; Habibi, Pedram; Moradmand-Badie, Banafsheh; Afsahi, Amir Masoud; Karimi, Amirali; Heydari, Mohammad; Mehraeen, Esmaeil; Dadras, Omid; Sabatier, Jean‐Marc; Voltarelli, Fabrí­cio Azevedo

doi:10.1186/s40001-021-00516-8

Cited by 80 publications

(83 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After two mutations, including the synonymous mutation T8782C and the non-synonymous mutation C28144T, by replacing serine with leucine in type A, type B is formed. Type C is also derived from type B by the non-synonymous mutation G26144T, in which valine replaces glycine [ 32 , 80 , 81 ]. In other words, the S variant (Type A) with two mutations at 8782C>T and 28144 T>C was mainly identified in East Asia.…”

Section: Discussionmentioning

confidence: 99%

Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review

et al. 2021

Self Cite

View full text Add to dashboard Cite

Introduction Coronavirus Disease-2019 (SARS-CoV-2) started its devastating trajectory into a global pandemic in Wuhan, China, in December 2019. Ever since, several variants of SARS-CoV-2 have been identified. In the present review, we aimed to characterize the different variants of SARS-CoV-2 and explore the related morbidity and mortality. Methods A systematic review including the current evidence related to different variants of SARS-CoV-2 and the related morbidity and mortality was conducted through a systematic search utilizing the keywords in the online databases including Scopus, PubMed, Web of Science, and Science Direct; we retrieved all related papers and reports published in English from December 2019 to September 2020. Results A review of identified articles has shown three main genomic variants, including type A, type B, and type C. we also identified three clades including S, V, and G. Studies have demonstrated that the C14408T and A23403G alterations in the Nsp12 and S proteins are the most prominent alterations in the world, leading to life-threatening mutations.The spike D614G amino acid change has become the most common variant since December 2019. From missense mutations found from Gujarat SARS-CoV-2 genomes, C28854T, deleterious mutation in the nucleocapsid (N) gene was significantly associated with patients' mortality. The other significant deleterious variant (G25563T) is found in patients located in Orf3a and has a potential role in viral pathogenesis. Conclusion Overall, researchers identified several SARS-CoV-2 variants changing clinical manifestations and increasing the transmissibility, morbidity, and mortality of COVID-19. This should be considered in current practice and interventions to combat the pandemic and prevent related morbidity and mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Multiple organ involvement is thought to occur due to the almost universal distribution of angiotensinconverting enzyme 2 (ACE-2) that attaches to SARS-CoV-2 spike (S) protein receptor binding domain (RBD) and type 2 transmembrane serine proteases (TMPRSS2) that cleaves the S protein. It is thought that both these molecules may initiate immune evasion through various mechanisms (10)(11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis

et al. 2021

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has resulted in a global pandemic, challenging both the medical and scientific community for the development of novel vaccines and a greater understanding of the effects of the SARS-CoV-2 virus. COVID-19 has been associated with a pronounced and out-of-control inflammatory response. Studies have sought to understand the effects of inflammatory response markers to prognosticate the disease. Herein, we aimed to review the evidence of 11 groups of systemic inflammatory markers for risk-stratifying patients and prognosticating outcomes related to COVID-19. Numerous studies have demonstrated the effectiveness of neutrophil to lymphocyte ratio (NLR) in prognosticating patient outcomes, including but not limited to severe disease, hospitalization, intensive care unit (ICU) admission, intubation, and death. A few markers outperformed NLR in predicting outcomes, including 1) systemic immune-inflammation index (SII), 2) prognostic nutritional index (PNI), 3) C-reactive protein (CRP) to albumin ratio (CAR) and high-sensitivity CAR (hsCAR), and 4) CRP to prealbumin ratio (CPAR) and high-sensitivity CPAR (hsCPAR). However, there are a limited number of studies comparing NLR with these markers, and such conclusions require larger validation studies. Overall, the evidence suggests that most of the studied markers are able to predict COVID-19 prognosis, however NLR seems to be the most robust marker.

show abstract

“… 14 Risk factors of COVID‐19 are related to the type of immune system response and host factors such as age, gender, underlying diseases, and so on. 15 , 16 , 17 , 18 …”

Section: Introductionmentioning

confidence: 99%

The clinical outcomes of COVID‐19 in HIV‐positive patients: A systematic review of current evidence

SeyedAlinaghi

MohsseniPour

Barzegary

et al. 2021

Immunity Inflam & Disease

Self Cite

View full text Add to dashboard Cite

Introduction Patients with chronic underlying diseases are more susceptible to coronavirus disease 2019 (COVID‐19) complications. Recent studies showed people living with HIV (PLWH) are not at greater risk than the general population. Few studies have reviewed the impacts of COVID‐19 on PLWH. The purpose of this systematic review was to investigate the impact of COVID‐19 on patients infected with HIV. Methods We executed a systematic search using four databases of PubMed, Scopus, Science Direct, and Web of Science and screened the records in two steps based on their title/abstract and full text. This study follows the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) checklist to elevate the validity and reliability of its results. Results We reviewed 36 studies. The patients' age was above 20 years in all studies. In almost all studies, the inflammatory parameters were reported high. In most of the studies, all HIV patients completely recovered from the COVID 19 infection. Although CD4 count was not recorded in all studies, the minimum level was reported as 12 cells/µl. Conclusion Based on the current review, we concluded that HIV patients at advanced stages (3 or 4) of the disease, whose CD4 counts are low, may show less severe COVID‐19 infection symptoms. Similarly, Interference can reduce the severity of immune reactions and subsequent cytokine storms and consequently mitigate the symptoms. Therefore, in most of the studies, the majority of HIV patients showed no severe symptoms and completely recovered from COVID 19 infection.

show abstract

Genetic susceptibility of COVID-19: a systematic review of current evidence

Cited by 80 publications

References 69 publications

Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review

Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review

Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis

The clinical outcomes of COVID‐19 in HIV‐positive patients: A systematic review of current evidence

Contact Info

Product

Resources

About